DOI QR코드

DOI QR Code

Clinical Study of Thalidomide Combined with Dexamethasone for the Treatment of Elderly Patients with Newly Diagnosed Multiple Myeloma

  • Chen, Hai-Fei (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Li, Zheng-Yang (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Tang, Jie-Qing (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Shen, Hong-Shi (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Cui, Qing-Ya (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Ren, Yong-Ya (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Qin, Long-Mei (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Jin, Ling-Juan (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Zhu, Jing-Jing (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Wang, Jing (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Ding, Jie (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Wang, Ke-Yuan (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command) ;
  • Yu, Zi-Qiang (Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Key Lab of Thrombosis and Hemostasis of Ministry of Health) ;
  • Wang, Zhao-Yue (Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Key Lab of Thrombosis and Hemostasis of Ministry of Health) ;
  • Wu, Tian-Qin (Department of Hematology, 100th Hospital of PLA, Medical Centre of Hematology & Oncology of Nanjing Military Command)
  • Published : 2012.09.30

Abstract

Objective: To investigate the relationship between the efficacy and safety of different doses of thalidomide (Thal) plus dexamethasone (Dex) as the initial therapy in elderly patients with newly diagnosed multiple myeloma (MM). Methods: Clinical data of 28 elderly patients with newly diagnosed MM who underwent the TD regimen as the initial therapy were analyzed retrospectively. The patients were divided into two groups according to the maximal sustained dose of Thal: lower dose (group A) and higher dose (group B). The overall response rate (ORR), progression free survival (PFS), overall survival (OS), and adverse events (AES) were compared between the two groups. Results: A total of 28 patients were followed up with a median of 18 months. The ORR was 60.1%. The median response time and PFS were 2.0 and 17.0 months, respectively. The mean sustained dose of Thal in group B was significantly higher than group A (292.9 mg v 180.4 mg, P=0.01). There was no significantly difference in ORR (57.1% v 64.3%, P=1.00) and PFS (9.63months v 17.66 months, P=0.73) between groups A and B. During the follow up, only five patients died (<40%) and, therefore, median OS values were not available. It is estimated, however, that the mean survival time in the two groups was 35.6 and 33.4 months (P>0.05), respectively. All of the patients tolerated the treatment well. The incidence of AES in patients with a grading above 3 in group B was significantly higher than in group A (P=0.033). Conclusions: The TD regimen results in a high response rate and manageable AES as the initial therapy in elderly patients with MM. TD should be considered as the front line regimen for the treatment of elderly patients with MM in areas with financial constraints. The clinical response can be achieved at a low dose Thal with minimal toxicity.

References

  1. Alexanian R, Haut A, Khan AU, et al (1969). Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA, 208, 1680-5. https://doi.org/10.1001/jama.1969.03160090040009
  2. Attal M, Harousseau JL, Stoppa AM, et al (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med, 335, 91-7. https://doi.org/10.1056/NEJM199607113350204
  3. Blade J, Cibeira MT, Rosinol L(2005). Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol, 44, 440-8. https://doi.org/10.1080/02841860510030002
  4. Cavallo F, Boccadoro M, Palumbo A (2007). Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Ther Clin Risk Manag, 3, 543-52.
  5. Child JA, Morgan GJ, Davies FE, et al(2003). High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl JMed, 348, 1875-83. https://doi.org/10.1056/NEJMoa022340
  6. Cohen HJ, Crawford J, Rao MK, et al (1998). Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med, 104, 439-44. https://doi.org/10.1016/S0002-9343(98)00080-1
  7. Durie BG, Harousseau JL, Miguel JS, et al (2006). International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-73. https://doi.org/10.1038/sj.leu.2404284
  8. Fukushima T, Nakamura T, Iwao H, et al (2011). Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res, 31, 2297- 302.
  9. Gay F, Hayman SR, Lacy MQ, et a l(2010). Lenalidomide plus dexamethasone versus Thal plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood, 115, 343-50.
  10. Gay F, Palumbo A (2011). Management of older patients with multiple myeloma. Blood Rev, 25, 65-73. https://doi.org/10.1016/j.blre.2010.10.003
  11. Gay F, Vincent Rajkumar S, Falco P, et al (2010). Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. Eur J Haematol, 85, 200-8. https://doi.org/10.1111/j.1600-0609.2010.01469.x
  12. Harousseau JL(2002). High-dose therapy in multiple myeloma. Ann Oncol, 13, S49-54.
  13. Hulin C, Facon T, Rodon T, et al (2007). Melphalan-Prednisone- Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients ${\geq}$75 Years with Multiple Melphalan-Prednisone (MP) in a Randomized, Double- Blind, Placebo-Controlled Trial, IFM 01/01. Blood, 110, 31a [Abstract 75].
  14. International Myeloma Working Group (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol, 121, 749-57. https://doi.org/10.1046/j.1365-2141.2003.04355.x
  15. Kastritis E, Dimopoulos MA (2007). Thalidomide in the treatment of multiple myeloma. Best Pract Res Clin Haematol, 20, 681-99. https://doi.org/10.1016/j.beha.2007.09.001
  16. Kyle RA, Rajkumar SV(2004). Multiple myeloma. N Engl J Med, 351, 1860-73. https://doi.org/10.1056/NEJMra041875
  17. Moreau P, Avet-Loiseau H, Facon T, et al (2011). Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood, 118, 5752-8. https://doi.org/10.1182/blood-2011-05-355081
  18. Palumbo A, Facon T, Sonneveld P, et al (2008). Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 111, 3968-77. https://doi.org/10.1182/blood-2007-10-117457
  19. Rajkumar SV, Blood E, Vesole D, et al (2006). Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed myeloma: a clinial trial coordinated by the Eastern Cooperative Group. J Clin Oncol, 24, 431-6. https://doi.org/10.1200/JCO.2005.03.0221
  20. Rajkumar SV, Hayman S, Gertz MA, et al (2002). Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol, 20, 4319-23. https://doi.org/10.1200/JCO.2002.02.116
  21. Rajkumar SV, Rosinol L, Hussein M, et al (2008). Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol, 26, 2171-7. https://doi.org/10.1200/JCO.2007.14.1853
  22. Saad AA, Sharma M, Higa GM (2009).Treatment of multiple myeloma in the targeted therapy era.Ann Pharmacother, 43, 329-38.
  23. San Miguel JF, Blade Creixenti J, Garcia-Sanz R (1999). Treatment of multiple myeloma. Haematologica, 84, 36-58
  24. Yakoub-Agha I, Mary JY, Hulin C, et al (2011). Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myelome. Eur J Haematol, 88, 249-59.

Cited by

  1. Genistein inhibits the proliferation of human multiple myeloma cells through suppression of nuclear factor-κB and upregulation of microRNA-29b vol.13, pp.2, 2015, https://doi.org/10.3892/mmr.2015.4740
  2. MicroRNAs in neutrophils: potential next generation therapeutics for inflammatory ailments vol.273, pp.1, 2016, https://doi.org/10.1111/imr.12450